Supremex Valuation

Is 557 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 557 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 557 (€2.64) is trading below our estimate of fair value (€8.15)

Significantly Below Fair Value: 557 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 557?

Key metric: As 557 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 557. This is calculated by dividing 557's market cap by their current revenue.
What is 557's PS Ratio?
PS Ratio0.3x
SalesCA$284.26m
Market CapCA$98.24m

Price to Sales Ratio vs Peers

How does 557's PS Ratio compare to its peers?

The above table shows the PS ratio for 557 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.6x
BNN BRAIN Biotech
1.3x8.5%€71.2m
DLX Delignit
0.3x10.2%€23.1m
NTG Nabaltec
0.6x5.1%€126.7m
2HRA H&R GmbH KGaA
0.1x3.0%€128.4m
557 Supremex
0.3x0.5%€98.2m

Price-To-Sales vs Peers: 557 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.6x).


Price to Sales Ratio vs Industry

How does 557's PS Ratio compare vs other companies in the European Forestry Industry?

0 CompaniesPrice / SalesEstimated GrowthMarket Cap
557 0.3xIndustry Avg. 0.7xNo. of Companies6PS00.40.81.21.62+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 557 is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Forestry industry average (0.7x).


Price to Sales Ratio vs Fair Ratio

What is 557's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

557 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio0.2x

Price-To-Sales vs Fair Ratio: 557 is expensive based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 557 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€2.64
€3.44
+30.2%
2.4%€3.52€3.35n/a2
Nov ’25€2.64
€3.55
+34.6%
7.0%€3.80€3.31n/a2
Oct ’25€2.68
€3.55
+32.6%
7.0%€3.80€3.31n/a2
Sep ’25€2.86
€3.55
+24.3%
7.0%€3.80€3.31n/a2
Aug ’25€2.72
€3.56
+31.0%
6.7%€3.90€3.39n/a3
Jul ’25€2.48
€3.56
+43.7%
6.7%€3.90€3.39n/a3
Jun ’25€2.46
€3.56
+44.9%
6.7%€3.90€3.39n/a3
May ’25€2.62
€3.65
+39.3%
8.8%€4.11€3.42n/a3
Apr ’25€2.66
€3.65
+37.2%
8.8%€4.11€3.42n/a3
Mar ’25€2.52
€3.65
+44.8%
8.8%€4.11€3.42n/a3
Feb ’25€2.84
€4.40
+54.9%
22.6%€5.75€3.38n/a3
Jan ’25€2.86
€4.40
+53.9%
22.6%€5.75€3.38n/a3
Dec ’24€2.36
€4.40
+86.5%
22.6%€5.75€3.38n/a3
Nov ’24€2.86
€5.36
+87.3%
12.1%€6.22€4.66€2.643
Oct ’24€3.14
€5.48
+74.4%
12.1%€6.11€4.59€2.684
Sep ’24€3.08
€5.48
+77.8%
12.1%€6.11€4.59€2.864
Aug ’24€4.26
€6.91
+62.2%
13.3%€8.37€5.93€2.724
Jul ’24€4.10
€6.91
+68.6%
13.3%€8.37€5.93€2.484
Jun ’24€3.94
€7.05
+78.9%
11.5%€8.15€6.21€2.463
May ’24€3.72
€7.09
+90.6%
11.5%€8.19€6.25€2.623
Apr ’24€3.88
€7.09
+82.7%
11.5%€8.19€6.25€2.663
Mar ’24€4.32
€6.60
+52.9%
4.4%€6.90€6.31€2.522
Feb ’24€4.96
€6.42
+29.5%
1.9%€6.54€6.30€2.842

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies